TIGIT and COVID-19: However, supported by previous reports that TIGIT blockade can restore the effector functions of TCD8+ cells during experimental sepsis38 and experimental model of chronic viral infection by LCMV39, we suggest that therapies aiming the TIGIT blockade would be beneficial in preventing nosocomial and opportunistic infections in hospitalized COVID-19 patients.